These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 23969971

  • 1. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ, Jiang H, Wu DL, Zheng JH.
    Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
    [Abstract] [Full Text] [Related]

  • 2. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous suppression of Src and signal transducer and activator of transcription 3 inhibits the growth of epithelial ovarian cancer cells.
    Lee SW, Yoo J, Lee SH, Kim D, Kim YM, Kim YT.
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul 03; 169(1):75-9. PubMed ID: 23427943
    [Abstract] [Full Text] [Related]

  • 4. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
    Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S, Ma D, Chen G, Gao Q.
    Biochem Biophys Res Commun; 2013 May 31; 435(2):188-94. PubMed ID: 23665025
    [Abstract] [Full Text] [Related]

  • 5. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.
    Cancer Chemother Pharmacol; 2011 Feb 31; 67(2):401-14. PubMed ID: 20443003
    [Abstract] [Full Text] [Related]

  • 6. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R.
    Tumour Biol; 2016 Oct 31; 37(10):14259-14269. PubMed ID: 27581819
    [Abstract] [Full Text] [Related]

  • 7. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 8. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan 01; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 9. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
    Al-Eisawi Z, Beale P, Chan C, Yu JQ, Proschogo N, Molloy M, Huq F.
    BMC Cancer; 2016 Aug 26; 16(1):688. PubMed ID: 27566066
    [Abstract] [Full Text] [Related]

  • 10. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
    Kandala PK, Srivastava SK.
    BMC Med; 2012 Jan 26; 10():9. PubMed ID: 22280969
    [Abstract] [Full Text] [Related]

  • 11. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, Silva IV, Rangel LBA.
    Pharmacol Rep; 2018 Jun 26; 70(3):409-417. PubMed ID: 29627688
    [Abstract] [Full Text] [Related]

  • 12. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
    Yan H, Guo BY, Zhang S.
    Biochem Biophys Res Commun; 2016 Feb 19; 470(4):947-54. PubMed ID: 26826383
    [Abstract] [Full Text] [Related]

  • 13. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 14. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, Lin F, Zhang Q, Zhao H, Zheng F.
    Int J Gynecol Cancer; 2013 Feb 01; 23(2):256-63. PubMed ID: 23358177
    [Abstract] [Full Text] [Related]

  • 15. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y.
    Oncotarget; 2017 Jun 13; 8(24):39154-39166. PubMed ID: 28388577
    [Abstract] [Full Text] [Related]

  • 16. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
    Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z.
    BMC Cancer; 2010 May 10; 10():187. PubMed ID: 20459702
    [Abstract] [Full Text] [Related]

  • 17. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J, Zhang L, Zhang X, Xing X.
    J Chemother; 2015 May 10; 27(6):358-64. PubMed ID: 25976336
    [Abstract] [Full Text] [Related]

  • 18. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
    Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P.
    Cell Cycle; 2008 Jan 01; 7(1):81-8. PubMed ID: 18196976
    [Abstract] [Full Text] [Related]

  • 19. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A.
    Oncotarget; 2015 Sep 15; 6(27):23720-34. PubMed ID: 26125441
    [Abstract] [Full Text] [Related]

  • 20. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
    Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Martí L, Ponce J, Molleví DG, Capella G, Condom E, Viñals F, Huertas D, Cuevas C, Esteller M, Avilés P, Villanueva A.
    Clin Cancer Res; 2012 Oct 01; 18(19):5399-411. PubMed ID: 22896654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.